Society of Hematologic Oncology
LightNews LightNews
banner
societyofhemonc.bsky.social
Society of Hematologic Oncology
@societyofhemonc.bsky.social
43 followers 22 following 220 posts
Get the latest news on sohoinsider.com, the official news source from SOHO.

Register for SBBC soho.click/SBBC
Become a member for free at soho.click/join.
Posts Replies Media Videos
societyofhemonc.bsky.social
Does the future of myeloma treatment belong to trispecific antibodies?

sohoinsider.com/multiple-mye...
November 19, 2025 at 2:50 AM
societyofhemonc.bsky.social
Tafasitamab gets positive CHMP opinion in R/R follicular lymphoma

sohoinsider.com/lymphoma/taf...
Tafasitamab gets positive CHMP opinion in R/R follicular lymphoma
Tafasitamab gets positive CHMP opinion in R/R follicular lymphoma. The opinion is based on results from the phase 3 inMIND trial.
sohoinsider.com
November 17, 2025 at 7:49 PM
societyofhemonc.bsky.social
FDA approves ziftomenib for relapsed or refractory NMP1-mutated AML
sohoinsider.com/meetings-con...
FDA approves ziftomenib for R/R NMP1-mutated AML
The US Food and Drug Administration has approved the menin inhibitor ziftomenib for treatment of relapsed or refractory NMP1-mutated acute myeloid leukemia in adult patients who have no alternative tr...
sohoinsider.com
November 15, 2025 at 1:55 AM
societyofhemonc.bsky.social
"We ... started these studies in the older patients because we were anxious about treating younger patients with chemotherapy-free regimens,"
Dr. Short says in this discussion with Dr. Hagop Kantarjian.

Watch the video:

sohoinsider.com/news/drs-kan...
November 14, 2025 at 4:42 AM
societyofhemonc.bsky.social
IDP-023 demonstrates good safety, efficacy in relapsed or refractory myeloma #SITC2025

sohoinsider.com/multiple-mye...
IDP-023: Safety, Efficacy in Relapsed/Refractory Myeloma - SOHO Insider
In a first-in-human study, IDP-023 showed promising safety and efficacy in relapsed/refractory multiple myeloma patients.
sohoinsider.com
November 13, 2025 at 1:49 AM
societyofhemonc.bsky.social
SOHO Young Investigator spotlight: Meet Maha Hameed, MD
@floridastate.bsky.social

sohoinsider.com/news/soho-yo...
SOHO Young Investigator spotlight: Meet Maha Hameed, MD - SOHO Insider
Maha Hameed, MD, brings a distinctive combination of scientific intrigue and personal drive to her work in hematologic oncology.
sohoinsider.com
November 11, 2025 at 10:54 PM
societyofhemonc.bsky.social
Watch our video interview with María-Victoria Mateos on the DREAMM-7 study on SOHO Insider.
sohoinsider.com/video-interv...
November 8, 2025 at 4:26 PM
societyofhemonc.bsky.social
DARZALEX FASPRO gets FDA approval to treat HR-SMM, approval based on phase 3 AQUILA study

sohoinsider.com/multiple-mye...
The FDA has approved DARZALEX FASPRO®
The FDA has approved DARZALEX FASPRO® as a single-agent therapy for adults with high-risk smoldering multiple myeloma (HR-SMM).
sohoinsider.com
November 7, 2025 at 8:02 PM
societyofhemonc.bsky.social
US FDA grants interchangeable designation for denosumab-bnht

sohoinsider.com/news/us-fda-...
US FDA grants interchangeable designation for denosumab-bnht
The US FDA granted interchangeable biosimilar designation to denosumab-bnht (Bomyntra) for patients with multiple myeloma (MM)
sohoinsider.com
November 5, 2025 at 2:33 AM
societyofhemonc.bsky.social
ICYMI: Drs. Susan O'Brien and Nitin Jain discuss FLAIR trial updates plus emerging BTK degraders in relapsed disease in this SOHO Insider podcast episode:

sohoinsider.com/leukemia/drs...
November 4, 2025 at 2:21 AM
societyofhemonc.bsky.social
Targeted immune CTCL therapy set for US launch in Q4 2025
sohoinsider.com/news/targete...
Targeted immune CTCL therapy set for US launch in Q4 2025
Citius Oncology signs exclusive agreement for denileukin diftitox-cxdl; Targeted immune CTCL therapy set for US launch in Q4 2025
sohoinsider.com
November 1, 2025 at 6:03 PM
societyofhemonc.bsky.social
"For a transplant-naive patient, we still can advocate to transplanting these patients if they're fit," Dr. Ibrahim T. Aldoss said in this panel discussion on #ALL with Dr. Elias Jabbour and Aaron Logan.

Watch the video: sohoinsider.com/news/drs-jab...
November 1, 2025 at 2:27 AM
societyofhemonc.bsky.social
Obesity increases infection risk in CLL for patients treated with a BTKi

sohoinsider.com/leukemia/obe...
Obesity increases infection risk in CLL
Patients with CLL who have a body mass index (BMI) of 40 or higher are at a greater risk of infection than patients with a normal BMI.
sohoinsider.com
October 31, 2025 at 10:01 PM
societyofhemonc.bsky.social
SOHO pilot program finds structured learning improves practice in R/R CLL/SLL

sohoinsider.com/news/soho-pi...
SOHO pilot program finds structured learning improves practice in R/R CLL/SLL - SOHO Insider
At the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), a new pilot program debuted to educate and empower the next generation of clinicians treating patients with relapse...
sohoinsider.com
October 30, 2025 at 6:27 PM
societyofhemonc.bsky.social
ICYMI: Daratumumab, bortezomib, lenalidomide, dexamethasone combo shows efficacy in myeloma across risk groups.
Daratumumab, bortezomib, lenalidomide, dexamethasone combo shows efficacy in myeloma across risk groups
By: Kerri Fitzgerald A study presented by Saad Usmani, MD, MBA, of the Memorial Sloan Kettering Cancer Center, as part of the SOHO 2025 Annual Meeting, showed that the combination of daratumumab,…
sohoinsider.com
October 28, 2025 at 10:27 PM
societyofhemonc.bsky.social
"People may think physicians become hardened, but the longer you do this, the more you understand what lies ahead for your patients" Gabriela Hobbs said in our Pathways & Perspectives! @massgeneralbrigham.bsky.social

sohoinsider.com/news/pathway...
Pathways & Perspectives with Gabriela Hobbs, MD - SOHO Insider
Dr. Hobbs, MPN lead and clinical director for the Adult Leukemia Service at Massachusetts General Hospital, was born in Mexico City, came to the US for college and her medical training.
sohoinsider.com
October 27, 2025 at 10:42 PM
societyofhemonc.bsky.social
FDA approves revumenib in relapsed or refractory NMP1-mutated #AML

sohoinsider.com/leukemia/fda...
FDA approves revumenib in relapsed NMP1-mutated AML
FDA approves revumenib in relapsed or refractory NMP1-mutated AML. Syndax announced the approval in a press release.
sohoinsider.com
October 24, 2025 at 9:10 PM
societyofhemonc.bsky.social
FDA approves blenrep combo in relapsed or refractory MM

sohoinsider.com/multiple-mye...
FDA approves blenrep combo in relapsed or refractory MM - SOHO Insider
The US Food and Drug Administration (FDA) has approved belantamab mafodotin-blmf; blenrep) in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed or r...
sohoinsider.com
October 23, 2025 at 8:36 PM
societyofhemonc.bsky.social
FDA grants orphan drug designation to MDS investigational therapy ofirnoflast

sohoinsider.com/news/fda-gra...
FDA has granted orphan drug designation to ofirnoflast
The FDA has granted orphan drug designation to ofirnoflast (HT-6184), an investigational therapy for myelodysplastic symptoms (MDS).
sohoinsider.com
October 23, 2025 at 5:26 PM
societyofhemonc.bsky.social
Despite digital advances, cancer research remains costly, burdensome
sohoinsider.com/leukemia/acu...
Despite digital advances, cancer research remains costly
Clinical cancer research remains too expensive and too burdensome, even amid a proliferation of digital tools designed to improve it, according to Ines Vaz-Luis, MD, PhD, who spoke at the 2025 Europea...
sohoinsider.com
October 23, 2025 at 12:43 PM
societyofhemonc.bsky.social
SOHO MENA returns to in-person meeting for region’s 3rd meeting
sohoinsider.com/myelodysplas...
SOHO MENA returns to in-person meeting for region’s 3rd meeting
SOHO MENA was held Sept. 25–27 in Beirut and marked a return to in-person collaboration after the meeting was held virtually the prior year.
sohoinsider.com
October 22, 2025 at 10:24 PM
societyofhemonc.bsky.social
Watch @NicholasShortMD with @DrHKantarjian at #SOHO2025 on the future of CAR-T in #ALL.

"I think the future... will be CAR-T cell consolidation...particularly for high-risk patients who otherwise might be referred for stem cell transplant."

Watch now: buff.ly/qvfnjX7
October 21, 2025 at 3:34 PM
societyofhemonc.bsky.social
ICYMI: VERONA phase 3 trial shows no survival benefit in high-risk MDS

sohoinsider.com/news/verona-...
VERONA phase 3 trial shows no survival benefit in high-risk MDS - SOHO Insider
The study, presented by Guillermo Garcia-Manero, MD, interim chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, evaluated the efficacy and safety of venetoclax i...
sohoinsider.com
October 21, 2025 at 2:35 AM
societyofhemonc.bsky.social
This Meet-the-Professor session with Uma Borate, MD, MS,
brought expert insight to #SOHO2025

sohoinsider.com/news/improvi...
Improving Outcomes in CHIP/CCUS with Dr. Borate - SOHO Insider
This Meet-the-Professor session was delivered by Uma Borate, MD, MS, at SOHO 2025 in Houston, Texas, in September 2025.
sohoinsider.com
October 16, 2025 at 9:29 PM
societyofhemonc.bsky.social
ICYMI: FDA grants orphan drug designation for AK117 (ligufalimab)
FDA grants Orphan Drug Designation for AK117 (ligufalimab)
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to AK117 (ligufalimab) for the treatment of acute myeloid leukemia (AML). Ligufalimab is a humanized IgG4 monoclonal…
buff.ly
October 16, 2025 at 8:22 PM